The short version of c-Met signaling fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2026-05-25 and is reviewed periodically as new material appears.
Dihexa is a synthetic peptidomimetic derived from angiotensin IV, a naturally occurring peptide fragment. It was created as a research compound to explore central nervous system signaling rather than as an approved therapeutic. Early work described it as a small, orally available molecule in rodent studies. Its structure combines tyrosine, isoleucine, and aminohexanoic acid components with a hexanoic acid cap. The compound is commonly referred to by the research code PNB-0408.
Development of dihexa followed from studies on angiotensin IV analogs and their effects on learning and memory. Researchers sought compounds with improved metabolic stability and brain penetration compared with natural peptides. In preclinical reports, dihexa was associated with changes in synaptic connectivity and performance on spatial tasks. These findings generated interest in its potential as a cognitive research tool. The work remains largely preclinical, and independent replication has been limited.
Regulatory and commercial contexts differ from clinical medicine. Dihexa is not approved as a drug by major agencies, and no published human trials establish its safety or efficacy. It is often sold as a research chemical labeled for laboratory use only. Suppliers may provide certificates of analysis, but purity and identity depend on the specific batch. Legal status varies by country and may treat such compounds as unapproved substances for human consumption.
In laboratory settings, dihexa is typically handled as a lyophilized peptide powder. Appropriate personal protective equipment and a ventilated workspace are standard practices for weighing and transferring research chemicals. Because the compound lacks regulatory approval for clinical use, it should not be given to people. Institutional safety rules and local regulations govern its acquisition, storage, and disposal. Suppliers often provide a certificate of analysis that lists purity, identity, and batch-specific handling notes.
Dissolution depends on the peptide’s salt form, purity, and the chosen solvent. Dimethyl sulfoxide is commonly used to prepare concentrated stock solutions, while aqueous buffers may show limited solubility. Sonication or gentle warming can sometimes aid dissolution, but excessive heat may promote degradation. Once in solution, the material is generally kept cold and protected from light. Researchers should verify solubility for each lot rather than assuming uniform behavior across suppliers.
Quality control usually combines reverse-phase high-performance liquid chromatography with mass spectrometry. Chromatography estimates purity and detects related impurities, while mass spectrometry supports molecular identity. Nuclear magnetic resonance can provide additional structural confirmation when needed. Stability data for dihexa are limited, and degradation pathways may depend on pH, temperature, and moisture. Open questions include long-term stability in different formulations and the effect of repeated freeze-thaw cycles on measured purity. Such tests help confirm that a batch matches its label before use.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic angiotensin IV analog | Peptidomimetic |
| Appearance | White to off-white powder | Lyophilized solid |
| Solubility | Soluble in DMSO; limited in water | Typical for small peptides |
| Storage | -20 °C, desiccated | Protect from light and moisture |
| Analytical method | HPLC with UV detection | Purity and identity checks |
Storage recommendations for peptides and peptide-like compounds usually emphasize low temperatures, desiccation, and protection from light. A common practice is to keep dry powder at -20 °C or below and to prepare solutions shortly before use. Repeated freeze-thaw cycles may degrade the material, so aliquoting is often advised. Solubility depends on the solvent; aqueous solubility may be limited, and organic solvents such as dimethyl sulfoxide are sometimes used for stock solutions. Stability data specific to dihexa are sparse, so general peptide handling guidelines are often applied instead.
Analytical confirmation generally combines a separation method with a detection method. Reverse-phase high-performance liquid chromatography can assess purity, while mass spectrometry supports molecular identity. For research-grade material, a certificate of analysis may report a batch-specific purity value, but it does not guarantee biological activity or safety. Regulatory frameworks vary by country; many jurisdictions treat dihexa as a research chemical not intended for human consumption. Purchasers should verify local rules and supplier documentation. The absence of official standards makes independent testing and careful record-keeping important for laboratory work.
The proposed mechanism of dihexa centers on activation of the hepatocyte growth factor receptor, also called c-Met. Some studies suggest it acts as a mimetic of hepatocyte growth factor, promoting signaling pathways involved in synapse formation. Other work has explored interactions with angiotensin IV pathways, but the exact binding targets remain uncertain. Laboratory findings come mainly from cell cultures and animal models. Whether these mechanisms operate similarly in humans is an open question. Researchers have not established a single, universally accepted mechanism of action.
Identity and purity of dihexa samples are typically assessed with high-performance liquid chromatography and mass spectrometry. These methods can confirm molecular mass and estimate the presence of impurities. However, a certificate of analysis from a supplier is not a guarantee of independent testing. Researchers often require in-house verification before using a peptide in experiments. For solid samples, appearance, solubility, and chromatographic profile provide additional checks. Nuclear magnetic resonance may be used for structural confirmation when available.
Dihexa is commonly handled as a lyophilized powder in laboratory settings. Storage at -20 °C in a desiccated, light-protected container is typical for peptides. Repeated freeze-thaw cycles can degrade the material, so aliquoting is often recommended. Aqueous solutions may be less stable than organic stocks and should be prepared fresh when possible. Personnel should follow institutional safety procedures and avoid uncontrolled exposure. Because human effects are not well characterized, handling precautions are prudent.
==== Role in myocardial growth and adaptation ==== Intracrine PTHrP has been implicated in myocardial development and adaptation to stress. It is particularly active during embryonic heart development, where it influences cardiomyocyte differentiation and growth. Additionally, under conditions of cardiac stress, such as ischemia or hypertrophy, PTHrP expression is upregulated, suggesting a protective role in maintaining myocardial function. Moreover, in vascular smooth muscle cells, intracrine PTHrP plays a dual role. While secreted PTHrP can inhibit cell proliferation via receptor-mediated pathways, intracellular PTHrP exerts a mitogenic effect, promoting vascular remodeling and adaptation in response to hemodynamic changes.
Bangladesh Council of Scientific and Industrial Research (BCSIR) (Bengali: বাংলাদেশ বিজ্ঞান ও শিল্প গবেষণা পরিষদ) is a scientific research organization and regulatory body of Bangladesh. Its main objective is to pursue scientific research for the betterment of the Bangladeshi people. It was established on 16 November 1973.
== Research == In July 2020 scientists reported that they have observed a voltage-induced transformation of normally diamagnetic pyrite into a ferromagnetic material, which may lead to applications in devices such as solar cells or magnetic data storage. Researchers at Trinity College Dublin, Ireland have demonstrated that FeS2 can be exfoliated into few-layers just like other two-dimensional layered materials such as graphene by a simple liquid-phase exfoliation route. This is the first study to demonstrate the production of non-layered 2D-platelets from 3D bulk FeS2. Furthermore, they have used these 2D-platelets with 20% single walled carbon-nanotube as an anode material in lithium-ion batteries, reaching a capacity of 1000 mAh/g close to the theoretical capacity of FeS2. In 2021, a natural pyrite stone was crushed and pre-treated followed by liquid-phase exfoliation into two-dimensional nanosheets, which showed capacities of 1200 mAh/g as an anode in lithium-ion batteries.
Sources: en.wikipedia.org
Once in the brain, the principal mode of action is as a nonselective antagonist of adenosine receptors (in other words, an agent that reduces the effects of adenosine). The caffeine molecule is structurally similar to adenosine, and is capable of binding to adenosine receptors on the surface of cells without activating them, thereby acting as a competitive antagonist. In addition to its activity at adenosine receptors, caffeine is an inositol trisphosphate receptor 1 antagonist and a voltage-independent activator of the ryanodine receptors (RYR1, RYR2, and RYR3). It is also a competitive antagonist of the ionotropic glycine receptor.
It is assumed that the globular ends are the sites for multivalent attachment to the complement fixing sites in immune complexed immunoglobulin. Patients with Lupus erythematosus often have deficient expression of C1q. Genetic deficiency of C1q is extremely rare (approximately 75 known cases) although the majority (>90%) of those have SLE. C1q associates with C1r and C1s in order to yield the C1 complex (C1qr2s2), the first component of the serum complement system. Deficiency of C1q has been associated with lupus erythematosus and glomerulonephritis. It is potentially multivalent for attachment to the complement fixation sites of immunoglobulin. The sites are on the CH2 domain of IgG and, it is thought, on the CH4 domain of IgM. IgG4 cannot bind C1q, but the other three IgG subclasses can. The appropriate peptide sequence of the complement fixing site might become exposed following complexing of the immunoglobulin, or the sites might always be available, but might require multiple attachment by C1q with critical geometry in order to achieve the necessary avidity.
== Causes == No clear cause for scleroderma and systemic sclerosis has been identified. Genetic predisposition appears to be limited, as genetic concordance is small; still, a familial predisposition for autoimmune disease is often seen. Polymorphisms in COL1A2 and TGF-β1 may influence severity and development of the disease. Evidence implicating cytomegalovirus (CMV) as the original epitope of the immune reaction is limited, as is parvovirus B19. Organic solvents and other chemical agents have been linked with scleroderma. One of the suspected mechanisms behind the autoimmune phenomenon is the existence of microchimerism, i.e. fetal cells circulating in maternal blood, triggering an immune reaction to what is perceived as foreign material. A distinct form of scleroderma and systemic sclerosis may develop in patients with chronic kidney failure. This form, nephrogenic fibrosing dermopathy or nephrogenic systemic fibrosis, has been linked to exposure to gadolinium-containing radiocontrast. Bleomycin (a chemotherapeutic agent) and possibly taxane chemotherapy may cause scleroderma, and occupational exposure to solvents has been linked to an increased risk of systemic sclerosis.
=== Stability and half-lives === Of isotopes whose half-lives are known, the lighter isotopes usually have shorter half-lives. The three lightest known isotopes have half-lives of <50 μs; the lightest reported isotope 252Rf has a half-life of <1 μs. 256Rf, 258Rf, 260Rf are more stable at ~10 ms; 255Rf, 257Rf, 259Rf, and 262Rf live between 1 and 5 seconds; 261Rf, 265Rf, and 263Rf are more stable, at ~1.1, 1.5, and 10 minutes respectively. The most stable known isotope, 267Rf, is one of the heaviest, and has a half-life of about 48 minutes. Rutherfordium isotopes with an odd neutron number tend to have longer half-lives than their even–even neighbors because the odd neutron hinders spontaneous fission. The lightest isotopes were synthesized by direct fusion between two lighter nuclei and as decay products. The heaviest isotope produced by direct fusion is 262Rf; heavier isotopes have only been observed as decay products of elements with larger atomic numbers. The heavy isotopes 266Rf and 268Rf have also been reported as electron capture daughters of the dubnium (266Db and 268Db), but have short half-lives to spontaneous fission. It seems likely that the same is true for 270Rf, a possible daughter of 270Db. These three isotopes remain unconfirmed. In 1999, American scientists at University of California, Berkeley, announced that they had succeeded in synthesizing three atoms of 293Og. These parent nuclei were reported to have successively emitted seven alpha particles to form 265Rf, but their claim was retracted in 2001.
Sources: en.wikipedia.org
=== Commander in Sichuan === After graduation, Liu Wenhui returned to Sichuan. There, Liu rejected an offer by fellow Baoding graduate Deng Xihou to serve under him. Instead, he met with his older nephew Liu Xiang, who recommended him to warlord Liu Cunhou of the Sichuan Army. Liu became a staff officer in Liu Cunhou's army, but before long, he had been transferred by Liu Xiang to the Eighth Division under General Chen Hongfan, stationed in Leshan. He was promoted rapidly from battalion commander to brigade commander over a period of five years from 1917 to 1922 due to the patronage of Liu Xiang. By 1919, he, along with his close friend Leng Yindong commanded around half of Chen's forces. His performance in the 1919-20 war to expel Yunnanese forces from Sichuan earned him the attention of Liu Chengxun, who promoted him. This caused tensions with Chen Hongfan, and Liu was subsequently forced to flee to Qingshen. The two would later reconcile, and Chen appointed Liu as a commander in the Yibin area. Yibin, at the confluence of the Jinsha and Min rivers, was known as a major trade port. Around the time of the anti-Yunnan campaign, Liu's parents died, and Liu was unable to return home for their funerals. In 1922, Liu Wenhui became a brigade commander at Yibin with his nephew Liu Xiang's help. This move gave him total control over the city. To collect more funds, Liu brought in his brother, Liu Wencai, as an economic official.
In 2001, the editors of 12 major journals issued a joint editorial, published in each journal, on the control over clinical trials exerted by sponsors, particularly targeting the use of contracts which allow sponsors to review the studies prior to publication and withhold publication. They strengthened editorial restrictions to counter the effect. The editorial noted that contract research organizations had, by 2000, received 60% of the grants from pharmaceutical companies in the US. Researchers may be restricted from contributing to the trial design, accessing the raw data, and interpreting the results. Despite explicit recommendations by stakeholders of measures to improve the standards of industry-sponsored medical research, in 2013, Tohen warned of the persistence of a gap in the credibility of conclusions arising from industry-funded clinical trials, and called for ensuring strict adherence to ethical standards in industrial collaborations with academia, in order to avoid further erosion of the public's trust. Issues referred for attention in this respect include potential observation bias, duration of the observation time for maintenance studies, the selection of the patient populations, factors that affect placebo response, and funding sources.
Since the tight control of enzyme activity is essential for homeostasis, any malfunction (mutation, overproduction, underproduction or deletion) of a single critical enzyme can lead to a genetic disease. The malfunction of just one type of enzyme out of the thousands of types present in the human body can be fatal. An example of a fatal genetic disease due to enzyme insufficiency is Tay–Sachs disease, in which patients lack the enzyme hexosaminidase. One example of enzyme deficiency is the most common type of phenylketonuria. Many different single amino acid mutations in the enzyme phenylalanine hydroxylase, which catalyzes the first step in the degradation of phenylalanine, result in build-up of phenylalanine and related products. Some mutations are in the active site, directly disrupting binding and catalysis, but many are far from the active site and reduce activity by destabilising the protein structure, or affecting correct oligomerisation. This can lead to intellectual disability if the disease is untreated. Another example is pseudocholinesterase deficiency, in which the body's ability to break down choline ester drugs is impaired. Oral administration of enzymes can be used to treat some functional enzyme deficiencies, such as pancreatic insufficiency and lactose intolerance. Another way enzyme malfunctions can cause disease comes from germline mutations in genes coding for DNA repair enzymes. Defects in these enzymes cause cancer because cells are less able to repair mutations in their genomes.
Sources: en.wikipedia.org
Dihexa is a synthetic peptidomimetic related to angiotensin IV. It is studied in preclinical research for effects on synaptic signaling and cognition. It is not an approved medication.
No major drug regulatory agency has approved dihexa for human use. Published human clinical trials are absent, so its safety and efficacy are not established. It is commonly sold for laboratory research only.
It was developed from research on angiotensin IV analogs and peptide stability. The goal was to find compounds with better brain penetration and metabolic resistance. Early studies used rodent models rather than human participants.
Typical storage is at -20 °C in a desiccated container protected from light. Repeated freeze-thaw cycles are usually minimized to reduce degradation. Specific conditions should follow the supplier’s documentation.